CliffBio
small molecule

UCERIS

BUDESONIDE

Loss of exclusivitySeptember 2031latest FDA-listed patent expiry
CompanySalix Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameUCERIS
Active ingredientBUDESONIDE
Strength9MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2013
Marketing statusRX

Listed patents

PatentExpiresType
9192581September 2031product
8895064September 2031product
10660858September 2031product
10307375September 2031product
9132093September 2031product

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

UCERIS patent cliff — loss of exclusivity September 2031 | CliffBio